Redenlab
measuring speech

Redenlab team

Expertise in speech and clinical trials

 

Adam vogel Phd

Adam Vogel PhD is Chief Science Officer and Founder of Redenlab. He leads its speech testing and analysis work. Adam has an international track record in developing speech tests to guide decisions about brain function and quality of life in clinical medicine and drug development.

Adam holds a PhD in behavioural neuroscience from The University of Melbourne and degrees in psychology and speech science from the University of Queensland, Australia. He is an Associate Professor and Director of the Centre for Neuroscience of Speech at The University of Melbourne, Australia and maintains strong research alliances with the leading clinical centres in Australia, Germany and the United States. 


 
 

Scientific team

Paul Maruff Phd

Paul Maruff PhD is Chief Science Officer at CogState Ltd, Australia and Professor at The Alzheimer’s Research Group at the Florey Institute of Neuroscience and Mental Health. He received his PhD in 1993 from LaTrobe University Melbourne, Australia. He is founder of CogState Ltd a company that develops cognitive tests specifically for the assessment of change in cognitive function in clinical trials and clinical practice. He is a member of the executive committee of the Australian Imaging Biomarkers and Lifestyle (AIBL) study and also serves as co-chair on the clinical panel of that study.

 

angela Morgan Phd

Professor Angela Morgan PhD consults to Redenlab on pediatric speech disorders. She is also Lead of the Speech and Language group at Murdoch Childrens Research Institute, Australia. Angela is a Speech Pathologist and National Health & Medical Research Council (Australia) Practitioner Fellow and has published in high impact journals including the British Medical Journal, Brain, Neurology, Neuroscience and Biobehavioural Reviews and Molecular Psychiatry. Her cross-disciplinary research program focuses on: (i) identification of new gene pathways leading to child speech and language disorders, (ii) conducting genotype-speech and language phenotype association studies for rare genetic syndromes and (iii) elucidating the neurobiology of speech and language disorders using quantitative brain imaging techniques.